Australia markets open in 9 hours 15 minutes

Cadrenal Therapeutics, Inc. (CVKD)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4499+0.0199 (+4.63%)
As of 10:44AM EDT. Market open.

Cadrenal Therapeutics, Inc.

822 A1A North
Suite 306
Ponte Vedra, FL 32082
United States
904 300 0701
https://www.cadrenal.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. Quang X. PhamChairman & CEO967kN/A1965
Mr. Matthew K. Szot CPA, CPACo-Founder & CFO594.89kN/A1974
Dr. Douglas W. Losordo FACC, FAHA, M.D.Chief Medical Officer528.69kN/A1958
Mr. Jeffrey ColeChief Operating OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Corporate governance

Cadrenal Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.